Option exercise and stock grant lift Coeptis (COEP) CEO’s share stake

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings CEO and President David Mehalick, a director and 10% owner, reported acquiring additional common stock on February 11, 2026. He exercised stock options to receive 148,875 shares of common stock at a weighted average exercise price of $7.05 per share.

On the same date, he also received a grant of 51,250 shares of restricted stock in an option exchange program, where previously underwater options were surrendered for stock. Following these transactions, Mehalick directly beneficially owns 330,192 shares of Coeptis common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mehalick David

Role CEO and President

Type	Security	Shares	Price	Value
Exercise	Common stock	148,875	$7.05	$1.05M
Grant/Award	Common Stock	51,250	$0.00	--

Holdings After Transaction: Common stock — 330,192 shares (Direct); Common Stock — 330,192 shares (Direct)

Footnotes (1)

1. Represents the weighted average exercise price of shares purchased upon exercise of stock options. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehalick David

(Last) (First) (Middle)

105 BRADFORD RD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		148,875	A	$7.05(1)	330,192	D
Common Stock	02/11/2026		A		51,250	A	$0(2)	330,192	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ David Mehalick	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did COEP CEO David Mehalick report on February 11, 2026?

David Mehalick reported acquiring Coeptis common stock through two transactions on February 11, 2026. He exercised stock options for 148,875 shares at $7.05 and received a grant of 51,250 restricted shares via an option exchange program.

How many COEP shares does David Mehalick own after the latest Form 4 filing?

After the reported transactions, David Mehalick directly beneficially owns 330,192 shares of Coeptis common stock. This figure reflects both the 148,875 shares from option exercises and the 51,250 restricted shares granted in the option exchange program.

Was the COEP insider transaction an open-market stock purchase or something else?

The transactions were not open-market purchases. One involved exercising stock options to acquire 148,875 common shares at a weighted average price of $7.05, while the other was a grant of 51,250 restricted shares issued through an option exchange program.

What is the significance of the $7.05 price in the COEP Form 4 filing?

The $7.05 figure represents the weighted average exercise price of common shares acquired when David Mehalick exercised stock options. It is the per-share price used in converting his derivative securities into 148,875 shares of Coeptis common stock.

What does the restricted stock grant in the COEP option exchange program represent?

The restricted stock grant represents 51,250 Coeptis shares issued to David Mehalick as part of an option exchange program. In this program, he surrendered underwater stock options in return for restricted stock, without paying a cash exercise price for those shares.

What roles does David Mehalick hold at Coeptis Therapeutics (COEP)?

David Mehalick serves as CEO, President, director, and a 10% owner of Coeptis Therapeutics Holdings. These roles indicate both executive and board-level responsibilities, as well as a significant ownership stake reflected in his 330,192 directly held common shares.